NASDAQ:SGMOSangamo Therapeutics Stock Price, Forecast & News

Sangamo Therapeutics' stock was trading at $7.02 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, SGMO stock has increased by 49.9% and is now trading at $10.52. View which stocks have been most impacted by Coronavirus.

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Sangamo Therapeutics in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Sangamo Therapeutics.

Sangamo Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, August 5th 2020. View our earnings forecast for Sangamo Therapeutics.

Sangamo Therapeutics Inc (NASDAQ:SGMO) released its earnings results on Monday, May, 11th. The biopharmaceutical company reported ($0.37) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.23) by $0.14. The biopharmaceutical company earned $13.10 million during the quarter, compared to analysts' expectations of $22.73 million. Sangamo Therapeutics had a negative return on equity of 22.68% and a negative net margin of 89.31%. The business's revenue was up 61.7% on a year-over-year basis. During the same quarter in the previous year, the firm earned ($0.41) EPS. View Sangamo Therapeutics' earnings history.

4 equities research analysts have issued 1 year price objectives for Sangamo Therapeutics' shares. Their forecasts range from $11.00 to $14.00. On average, they expect Sangamo Therapeutics' share price to reach $12.50 in the next twelve months. This suggests a possible upside of 18.8% from the stock's current price. View analysts' price targets for Sangamo Therapeutics.

Media stories about SGMO stock have been trending negative on Tuesday, according to InfoTrie Sentiment. The research firm rates the sentiment of press coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Sangamo Therapeutics earned a daily sentiment score of -2.1 on InfoTrie's scale. They also assigned media headlines about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the stock's share price in the next several days. View the latest news about Sangamo Therapeutics.

Some companies that are related to Sangamo Therapeutics include Amgen (AMGN), Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX), Celgene (CELG), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), Seattle Genetics (SGEN), Alexion Pharmaceuticals (ALXN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Immunomedics (IMMU) and Ionis Pharmaceuticals (IONS). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Sangamo Therapeutics investors own include NVIDIA (NVDA), Crispr Therapeutics (CRSP), Advanced Micro Devices (AMD), Micron Technology (MU), Novavax (NVAX), Gilead Sciences (GILD), Brainstorm Cell Therapeutics (BCLI), Alibaba Group (BABA), Editas Medicine (EDIT) and Intel (INTC).

Sangamo Therapeutics trades on the NASDAQ under the ticker symbol "SGMO."

Sangamo Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Diversified Trust Co (0.01%). Company insiders that own Sangamo Therapeutics stock include Edward R Conner, H Stewart Parker, Joseph S Zakrzewski, Kathy Yi and Stephen George Dilly. View institutional ownership trends for Sangamo Therapeutics.

SGMO stock was purchased by a variety of institutional investors in the last quarter, including Diversified Trust Co. Company insiders that have bought Sangamo Therapeutics stock in the last two years include H Stewart Parker, and Joseph S Zakrzewski. View insider buying and selling activity for Sangamo Therapeutics.

Shares of SGMO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of SGMO stock can currently be purchased for approximately $10.52.

Sangamo Therapeutics has a market capitalization of $1.48 billion and generates $102.43 million in revenue each year. The biopharmaceutical company earns $-95,190,000.00 in net income (profit) each year or ($0.85) on an earnings per share basis. Sangamo Therapeutics employs 302 workers across the globe.

The official website for Sangamo Therapeutics is www.sangamo.com.

Sangamo Therapeutics' mailing address is 7000 MARINA BLVD, BRISBANE CA, 94005. The biopharmaceutical company can be reached via phone at 510-970-6000 or via email at [email protected]